



Dr. André ZIEGLER, Roche Diagnostics

André Ziegler (Rotkreuz, Switzerland)

André Ziegler is Global Clinical Leader for Cardiovascular Diseases at Roche Diagnostics International. He studied Pharmacy at the Universities of Basel and Geneva (Switzerland). He holds a PhD in cardiac metabolism from the Basel University. He worked as a postdoctoral researcher at the Boston University Medical School and the Institute of Molecular Biology (Biozentrum) at Basel University with various clinical methods (e.g. cardiac MRI, clinical mass spectrometry), institutes (Basel University Hospital, Institute for Pharmaceutical Sciences) and several diagnostic and pharmaceutical industries. In Roche, he is responsible for the clinical studies used for global registrations of cardiac solutions and all clinical development programs for new cardiac biomarkers (e.g. heart failure, atrial fibrillation, coronary artery disease) and instruments (e.g., cardiac point of care solutions). André is convinced that the therapeutic progress in Oncology in the last 20 years through personalized healthcare can be translated in parts also to cardiology by closer collaboration of the research partners, better therapy stratification and identification of new biotargets. Interdisciplinary collaboration for research has always been a central focus of his activities. He contributed to several FP7/Horizon 2020/Europe consortia, North American academic consortia and initiated collaborations of Diagnostics with >10 pharmaceutical companies, and Global Clinical Chemistry associations (e.g. IFCC). Lately he has expanded his responsibilities at Roche to all clinical activities and to diagnostic solutions in Acute Care Medicine, Coagulation and Hematology. Roche Diagnostics is globally active in all market segments, from clinical research and clinical laboratory systems to patient self-monitoring. In the CRT, André is active since 2016 and had contributed to the nucleus from 2018 to 2021.